TD Cowen raised its price target on Kiniksa Pharmaceuticals International PLC (KNSA) to $115 from $100 and kept a Buy rating, naming the rare-disease drugmaker one of its Best Ideas for 2027 as it builds a case around wider use of the company's flagship therapy and a cheaper-to-produce successor still in late-stage testing.
The firm's thesis rests on Arcalyst, an injectable treatment for recurrent pericarditis, an inflammation of the sac around the heart. More than five years after launch, the drug is still adding roughly $25 million in sales each quarter, according to analyst Nicholas Lorusso, who wrote that the product has so far reached only about 23% of the estimated 14,000 U.S. patients who suffer multiple recurrences. Another 26,000 patients with a first recurrence represent untapped demand, he added.
Prescriber penetration looks similarly thin. Kiniksa has won over just 18% of roughly 30,000 potential prescribers, leaving what the analyst described as substantial room to expand.
TD Cowen's 2027 model assumes Arcalyst adds only $12 million sequentially each quarter, less than half the $25 million average of the past six quarters. That gap, the firm argues, leaves room for estimates to be revised higher.
Note: EPS figures reflect TD Cowen estimates based on 2027 Arcalyst revenue projections.
The larger prize, in the firm's view, is KPL-387, a wholly owned IL-1 receptor antagonist that could be given once a quarter through an autoinjector instead of Arcalyst's weekly shot, cutting annual injections from 52 to 12. Better convenience could improve adherence, which matters clinically because symptoms have returned when Arcalyst treatment was interrupted. Late-stage Phase III results are due in the second half of 2027.
Because Arcalyst carries collaboration costs equal to about 35% of its revenue while KPL-387 would be owned outright, removing that drag on the 2027 revenue base could add roughly $6 to earnings per share, a potential increase of about 400%, the analyst estimated.
Beyond that, TD Cowen pointed to KPL-1161, a quarterly subcutaneous IL-1 therapy that could take Kiniksa beyond recurrent pericarditis, as well as possible business development deals. The $115 target is derived from a discounted cash flow model that assumes Arcalyst keeps growing and KPL-387 makes a successful transition.
For investors, the call frames Kiniksa as a commercial-stage story with a second act: near-term revenue growth from an underpenetrated franchise, then a potential margin step-up if the pipeline drug succeeds and replaces collaboration payments with wholly owned economics. The main risk sits in the binary nature of the 2027 Phase III readout, which must validate both the dosing profile and the adherence benefit the bull case depends on.
Once added, BigGo Finance appears first in Google Search Top Stories, so you get the broadest, most up-to-the-minute, and most comprehensive global financial news first.



